Clinical Trial Update: Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating docetaxel with or without low-dose, short-course sunitinib in refractory solid tumors, including breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Sunitinib (sunitinib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Solid Tumors, Breast Cancer | Phase 2 | Status: UNKNOWN